The Centre for Digestive Diseases

Recent Publications & Abstracts

Publications

• Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
  T.J. Borody, G. Pang, A. R. Wettstein, R. Clancy, K. Herdman, R. Surace, R. Llorente, C. Ng.
  Aliment Pharmacol Ther 2006; 23: 481-488.


• Selective reduction of anti-Helicobacter pylori IgG subclass antibody in gastric carcinoma.
  T. Borody, Z. Ren, G. Pang, LC. Li, M. Dunkley, R. Clancy.
  Journal of Gastroenterology and Hepatology 2005; 20: 1338-1343.


• Probiotics under the regulatory microscope.
  T. Borody, A. Henriksson, R. Clancy.
  Expert Opin. Drug Saf. 2005; 4(6):


• Anti-MAP therapy in the treatment of active Crohn's disease.
  T.J. Borody, R. Clancy, A. Wettstein, K.J. Herdman, M. Torres, S. Tye, G. Pang, E. Campbell, S. Leis.
  Journal of Gastroenterology and Hepatology 2005; 20(Suppl): A2.


• Evaluation of anti-Helicobacter pylori IgG2 antibody for the diagnosis of Helicobacter pylori infection in western and Chinese populations.
  T. Borody, Z. Ren, G. Pang, M. Dunkley, R. Clancy, H. H. X. Xia, K. M. Chu & J. Wong.
  Aliment Pharmacol Ther 2005; 21: 83-89.


• How effective are quadruple therapies as first-line H. pylori eradication therapies?
  TJ Borody.
  Nature Clinical Practice - Gastroenterology & Hepatology 2005; 2: 174-175 (Practice Point).


• Bacteriotherapy using fecal flora: toying with human motions.
  TJ Borody, EF Warren, SM Leis, R Surace, O Ashman, S Siarakas.
  J Clin Gastroenterol 2004; 38(6): 475-83.


• Lactoferrin: milking ulcers?
  TJ Borody, O Ashman.
  Digest Liver Dis 2003; 35: 691-3.


• Treatment of ulcerative colitis using fecal bacteriotherapy.
  TJ Borody, EF Warren, S Leis, R Surace, O Ashman.
  J Clin Gastroenterol 2003; 37(1): 42-7.


• Impaired host immunity contributes to Helicobacter pylori eradication failure.
  T Borody, Z Ren, G Pang, R Clancy.
  Am J Gastroenterol 2002; 97(12): 3032-7.


• Irritable bowel syndrome and Dientamoeba fragilis.
  TJ Borody, C Robertson, A Wettstein, E Warren, R Surace.
  IBIS News and Views. Winter 2002; 4-5.


• Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure?
  TJ Borody, S Leis, EF Warren, R Surace.
  Digest Liver Dis 2002; 34(1): 29-38.


• Skewered diverticulum: another cause of abdominal pain.
  A Wettstein, T Borody, E Warren.
  Internal Med J 2001; 31(8): 495-6.


• Shift of the gastric T-Cell response in gastric carcinoma.
  Z Ren, G Pang, R Clancy, LC Li, C Soon-Lee, R Batey, T Borody, M Dunkley.
  Helicobacter 2001; 16(2): 42-8.


• Response to "Fecal bacteriotherapy or probiotics for the treatment of intestinal diseases?"
  TJ Borody.
  Am J Gastroenterol 2001; 96: 2262-3.


• Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy.
  WA de Boer, TJ Borody.
  Digest Liver Dis 2000. 32: 673-5.


• Circulating T-cell response to H. pylori infection in chronic gastritis.
  Z Ren, G Pang, R Lee, R Batey, M Dunkley, T Borody, R Clancy.
  Helicobacter 2000; 5(3): 135-41.

Abstracts

• Effects of supplemental oxygen during endoscopy.
  T.J. Borody, S. Ramrakha, G. Pang, K. Herdman, E. Campbell, M. Torres.
  Journal of Gastroenterology and Hepatology 2005; 20(Suppl): A49.


• Is Crohn's on the MAP yet?
  TJ Borody.


• Novel appearance of healing mucosa following anti-Mycobacterium avium paratuberculosis therapy for Crohn's disease.
  TJ Borody, SM Leis, J Chongnan, R Surace, K Herdman, P Recabarren, O Ashman.
  J Gastroenterol Hepatol 2004; 19(Suppl): A210.


• Use of hyperlac in Coeliac disease and its effect on disaccharidase deficiency.
  TJ Borody, KJ Herdman, A Wettstein, R Surace, D Alexander.
  J Gastroenterol Hepatol 2004; 19(Suppl): A222.


• Dientamoeba fragilis (Df) and Irritable Bowel Syndrome (IBS).
  TJ Borody, AR Wettstein, KJ Herdman, SM Leis, RA Llorente, M Torres, R Surace.
  ASM Sydney National Conference 2004; page 17.


• Can the response to eradication therapy in Helicobacter pylori infection be predicted?
  R Clancy, T Borody, Z Ren, G Pang.
  Can J Gastroenterol 2004; 17(Suppl.B): 58B-61B.


• Faecal bacteriotherapy (FB) for chronic C. difficile syndromes.
  TJ Borody, SM Leis, J Chongnan, A Wettstein, K Herdman, RA LLorente, P Recabarren, EF Warren, O Ashman.
  J Gastroenterol Hepatol 2003; 18: B8.


• Varying gastric sensitivities of H. pylori.
  TJ Borody, R Clancy, EF Warren, R Surace, S Brusentsev, H Mitchell.
  J Gastroenterol Hepatol 2002; 17(Suppl): A102.


• Eradication of Dientamoeba fragilis can resolve IBS-like symptoms.
  TJ Borody, EF Warren, A Wettstein, G Robertson, Fontela A Recabarren, K Herdman, R Surace.
  J Gastroenterol Hepatol 2002; 17(Suppl): A103.


• Effects of supplement oxygenation during endoscopy.
  SC Ramrakha, TJ Borody, G Pang, K Herdman, E Campbell.


• Rifabutin - the key to H. pylori rescue therapy?
  TJ Borody, EF Warren, P Recabarren, K Herdman, R Surace.
  J Gastroenterology Hepatol. 2002; 17(Suppl): A102.


• Direct antibiotic susceptibility testing of Helicobacter pylori: does it have a role?
  V Sintchenko, P Veroerd, H Mitchell, J Sacco, TJ Borody.
  J Gastroenterol Hepatol 2001; 16: A35.


• A high level of primary resistance to metronidazole and clarithromycin in previously untreated symptomatic patients presenting for endoscopy in Australia.
  HM Mitchell, S Brusentsev, SL Hazell, T Borody, G Daskalopoulos, R Bradbear.
  Gut 2000; 47: A107.


• Flora power - fecal bacteria cure chronic C. difficile diarrhea (editorial).
  TJ Borody.
  Am J Gastroenterol. 2000; 95(11): 3028-3029.


• Treatment of severe Crohn's disease using rifabutin-macrolide-clofazimine combination - results at 38-43 months.
  TJ Borody, S Leis, R Surace, E Warren, E Lim.
  J Gastroenterol Hepatol 2000; 15: J102.


• Treatment of severe Crohn's disease (CD) using rifabutin-macrolide-clofazimine combination: results at 30-37 months.
  TJ Borody, S Leis, R Surace, J Goodger.
  Gastroenterology 2000; 118: A1334.